康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 01-15 16:00:00 EST

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778227200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO/tweets","defaultTab":"tweets","newsList":[{"id":"2630045413","title":"智通港股解盘 | 各种负面冲击恒指出现调整 4月金股药明康德(02359)引领CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2630045413","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630045413?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:21","pubTimestamp":1777378875,"startTime":"0","endTime":"0","summary":"拟套现约 4.9 亿，此前累计套现 13.4 亿，今天跌超 12%。一解禁抛盘汹涌，下跌超 16%。截至 2026 年 3 月末，持续经营业务在手订单 597.7亿元，同比增长 23.6%，为全年业绩提供较强可见度。希腊船舶经纪公司 Exclusive27 日表示，由于霍尔木兹海峡通航受限，部分油轮被滞留，可用运力减少。航线不确定性加剧推动油轮短期租赁运费飙升。此外，公司宣布派发末期股息每股 35 港仙。出口量稳居高位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCHmain","LU0348766576.USD","LU0348767384.USD","603259","BK1583","LU1997245177.USD","LU2495084118.USD","VXUS","LU1046422090.SGD","LU0052750758.USD","BK1576","LU1969619763.USD","LU2242644610.SGD","HSImain","02359","LU0456842615.SGD","LU1997244956.HKD","LU0320764599.SGD","LU0708995583.HKD","BK1171","BK1548","HSI","513600","BK1507","00317","LU2045819591.USD","CXO","LU1808992512.USD","LU2488822045.USD","HHImain","MHImain","BK1183","00631","BK1505","BK0216","02039","LU1934453819.USD","BK4588","BK4585","LU1979443071.USD","LU2125910500.SGD","BK1141","LU1997245094.SGD","02833","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630132145","title":"别只盯着AI！CXO龙头绩后狂飙，医药赛道要接棒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630132145","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630132145?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:12","pubTimestamp":1777349565,"startTime":"0","endTime":"0","summary":"新一轮行情蓄势待发？","market":"sg","thumbnail":"https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4574522","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1515","CXO","002821","LU2125910500.SGD","LU0320764599.SGD","02359","603127","LU0348766576.USD","06127","159938","BK1583","BK1574","LU1328615791.USD","LU0052750758.USD","BK0239","06821","BK1191","BK0216","09939","AIPO","LU1046422090.SGD","LU0708995583.HKD","BK1576","AGIX","ARTY","CHAT","LU0348767384.USD","LU2045819591.USD","BK0132","LU2242644610.SGD","BK1161","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630340844","title":"“CXO一哥”一季度营收首破“百亿”，A、H股CXO概念走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2630340844","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630340844?lang=zh_cn&edition=full","pubTime":"2026-04-28 10:01","pubTimestamp":1777341660,"startTime":"0","endTime":"0","summary":"早盘，A股CXO概念走强，凯莱英、药明康德涨停，博腾股份、康龙化成、毕得医药、诚达药业等跟涨。港股方面，药明康德涨超16%，药明生物、康龙化成、泰格医药等跟涨。消息面上，4月27日，“CXO一哥”药明康德公告称，2026年第一季度实现营业收入124.36亿元，同比增长28.81%，首次在第一季度迈入百亿大关；归属于上市公司股东的净利润为46.52亿元，同比增长26.68%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721714535.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721714535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630786369","title":"三个月股价几近“腰斩”，维亚生物(01873)为何没跟上CXO企稳反弹脚步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630786369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630786369?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:08","pubTimestamp":1777280903,"startTime":"0","endTime":"0","summary":"在今年1月底股价反弹至阶段性高点2.86港元之后，维亚生物的股价便开始了一段近3个月的下跌行情。3月30日，维亚生物正式披露公司2025年年度业绩。没跟上CXO企稳反弹脚步?近期，AH两地CXO企业已陆续披露2025年年报。以维亚生物为例，近三个月来，维亚生物股价持续回调。可以看到，维亚生物股价3月17日之后进一步阴跌，并且后续股价一直在BOLL线中下轨震荡，市场情绪低迷。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01873","BK1576","BK1141","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628395711","title":"中国银河证券：CXO助力小核酸加速发展 国产管线蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2628395711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628395711?lang=zh_cn&edition=full","pubTime":"2026-04-20 13:44","pubTimestamp":1776663860,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，小核酸产业链国内处于起步阶段，国产替代空间大，CXO助力行业加速发展。中游CDMO企业提供小核酸药物外包研发服务，助力国内小核酸药物行业的快速发展。中国银河证券主要观点如下：从小核酸药物英克司兰跻身重磅药物行列，看小核酸药物高成长属性诺华2025年度财报：全球首款siRNA超长效降脂药Leqvio全年销售额飙至11.98亿美元，同比增长57%，跻身重磅药物行列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","BK1564","06881","BK0188","BK1147","BK0276","CXO","601881"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221164","title":"港股异动 | CXO 概念股跌幅居前 海外投融资大环境进入波动阶段 AI制药或导致研发及临床端分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221164?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:31","pubTimestamp":1776396664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CXO概念股跌幅居前，截至发稿，昭衍新药跌5.82%，报21.7港元；康龙化成跌3.65%，报21.1港元；泰格医药跌3.02%，报42.46港元。中信建投发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1576","03759","BK4585","AGIX","BK1141","CXO","03347","VXUS","CHAT","BK1191","01477","ARTY","BK1583","BK4588","06127","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257476","title":"东方证券：医药生物行业CXO景气上行 重视安评弹性和龙头重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257476","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627257476?lang=zh_cn&edition=full","pubTime":"2026-04-16 09:19","pubTimestamp":1776302394,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，从医药生物业CXO景气度指标最新数据来看：2026Q1，国内融资向好趋势加强，早期研发管线备受青睐。订单端：安评限速，龙头重估1）安评：订单加速，猴子成瓶颈。临床前CRO，尤其是安全性评价，是本轮BD驱动的早期研发最受益方向。需求火热叠加实验猴供给受限，将会带来实验猴和CRO服务价格双升，成为新一轮国内创新药上行周期中弹性最大的细分方向；2）CDMO：全球冠军，近在咫尺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["000808.SH","CXO","BK1564","163118","BK0276","600958","BK0028","BK0012","03958","BK0188","BK1147","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627325669","title":"A股药企薪酬图鉴 创新药、CXO、高端医疗器械赛道人均薪酬领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2627325669","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627325669?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:00","pubTimestamp":1776294000,"startTime":"0","endTime":"0","summary":"随着A股年报相继出炉，各企业年薪再次成为焦点。截至2026年4月初，A股已有130家医药生物上市公司完整披露2025年人均薪酬数据。同花顺问财数据显示，医药行业内部薪酬分化极为显著，创新药、CXO、高端医疗器械三大赛道凭借高研发投入与技术壁垒，人均薪酬遥遥领先；而传统仿制药、中药、医药流通等领域则深陷薪酬洼地，行业最高与最低企业年薪差距超8倍。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159982","159883","09996","159992","BK1161","09997","399300","CXO","06978","BK1100","BK1583","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627286159","title":"结构性分化复苏趋势明显，触底反弹的内需成头部CXO增长的“关键先生”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627286159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627286159?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:06","pubTimestamp":1776251203,"startTime":"0","endTime":"0","summary":"CDMO赛道回归增长轨道受益于新分子需求快速增长及国内市场在BD驱动下的显著改善，2025年国内CXO公司订单整体处于环比持续向好的趋势，其中CDMO企业表现较其他细分赛道更为亮眼。根据国金证券统计数据，国内头部CDMO企业在2025年的订单增量均有出色表现。截至报告期末，公司待执行合同金额达182亿元，同比增长15.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627623478","title":"中信建投：持续看好CXO板块成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2627623478","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627623478?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:42","pubTimestamp":1776210169,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投证券发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。AI制药双刃剑，研发及临床端存在分化，生产端整体利好：AI对制药及与医药外包行业虽然影响短期有限、但市场对新技术对长期的行业发展变革的影响已初步达成共识。积极布局AI技术的公司有望在新的产业趋势下延续生命周期、看到新的机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","601066","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627338194","title":"申万宏源：26年一季报披露期临近 关注创新药、CXO及上游","url":"https://stock-news.laohu8.com/highlight/detail?id=2627338194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627338194?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:10","pubTimestamp":1776067851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，截止至4月12日共有8家医药上市公司发布2026Q1业绩预告，其中6家利润同比增长，2家同比下滑。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期，重点推荐。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期其中，CXO板块的业绩增长主要得益于全球创新药行业景气度持续向好，行业新签订单呈现良好增长，国内外医药投融资景气度持续上行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","CXO","000166","BK0276","BK1574","06806","159992","BK0028","BK0183","06978","BK1564","BK1161","BK0012","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626162468","title":"西南证券：风险出清+双轮驱动 CXO有望开启景气上行周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2626162468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626162468?lang=zh_cn&edition=full","pubTime":"2026-04-10 15:20","pubTimestamp":1775805627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，2026年一季度，CXO板块风险出清、业绩分化、双轮驱动，板块有望进入新一轮景气上行周期。2026年一季度，CXO板块风险出清、业绩分化、双轮驱动：美国政策不确定性缓和，地缘压制消退、估值修复动力足;龙头(药明系)与CDMO业绩高增、临床CRO企稳，结构性行情显著;海外研发回暖+国内创新药市场修复共振，订单饱满锁定2026-2027年增长，板块有望进入新一轮景气上行周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600369","BK0012","BK0276","CXO","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917325","title":"创新药与CXO联袂走强：共振修复后市走势如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917325","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625917325?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:44","pubTimestamp":1775641440,"startTime":"0","endTime":"0","summary":"4月以来，A股医药板块迎来全面回暖，再现一波“吃药”行情。其中A股医药板块迎来全面回暖，创新药与CXO（医药研发及生产外包）两大核心赛道联袂上演强势反弹行情，形成鲜明的产业链共振效应，成为市场资金布局的核心焦点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083698149210.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698149210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK1161","CXO","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625788996","title":"国信证券：全球生物医药投融资复苏 助推CXO行业需求向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2625788996","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625788996?lang=zh_cn&edition=full","pubTime":"2026-04-08 10:19","pubTimestamp":1775614767,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，全球生物医药投融资明确复苏，2025年融资额同比增长4%，为CXO行业注入增长动力。CDMO方面，全球药品市场的平稳增长为CDMO行业筑牢需求根基，新分子疗法的爆发式增长更开辟了核心增量空间；CRO方面，作为研发链条的核心环节，其受投融资复苏的驱动更为直接，业绩兑现的确定性与增长弹性显著增强，行业景气度持续上行。临床前CRO领域，实验动物相关订单已率先触底反弹，后续增长确定性增强。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","002736","161726","399441","XBI","BK4581","BK0188","BK0183","CXO","BK0028","BK0276","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524244","title":"中金：把握外需韧性兑现与内需触底复苏 坚定看好当前CXO板块布局机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524244","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524244?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:30","pubTimestamp":1775100600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，坚定看好当前CXO板块的布局机会。中金主要观点如下：事件CXO龙头公司2025年年报陆续披露：1)海外需求驱动的CDMO公司订单、业绩与产能投放延续良好经营态势，2026 年收入普遍指引双位数增长，彰显管理层信心;2)内需导向的临床CRO、安评CRO显现“订单量价齐修复”的复苏信号，从“订单修复”向“业绩兑现”阶段过渡，2026 年有望在订单执行带动下逐步传导至利润表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","LU0039217434.USD","LU0181495838.USD","02359","LU1046422090.SGD","LU0516423174.USD","06821","LU0456827905.SGD","03347","LU0856984785.SGD","LU1688375341.USD","LU0051755006.USD","LU0823426480.USD","LU0516422366.SGD","LU0327786744.USD","LU1328615791.USD","LU3063872942.SGD","LU0516423091.SGD","02269","LU0516422440.USD","002821","HK0000306685.HKD","LU0417516738.SGD","BK1521","LU0320764599.SGD","LU0979878070.USD","LU1242518857.USD","BK1576","06127","IE00B0JY6N72.USD","LU0823426308.USD","LU0348735423.USD","BK1589","LU0052750758.USD","LU0140636845.USD","LU0359201612.USD","LU0043850808.USD","LU0572944931.SGD","HK0000306701.USD","03759","LU0326950275.SGD","LU1794554557.SGD","LU0307460666.USD","01548","LU2045819591.USD","LU1880383366.USD","LU0456846285.SGD","LU0588546209.SGD","LU0348825331.USD","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1617","LU0348766576.USD","01789","LU1115378108.SGD","LU0348735423.USD","02228","LU0307460666.USD","BK1141","09688","LU2328871848.SGD","LU2476274308.USD","LU1794554557.SGD","LU2778985437.USD","03933","LU1770034418.SGD","LU2399975544.HKD","LU1303224171.USD","LU0417516738.SGD","LU0417516902.SGD","BK1593","01099","09926","02268","01530","BK1191","02367","BK1207","BK1585","CXO","LU0348784397.USD","LU2476274720.SGD","BK1574","LU0417516571.SGD","02196","IE00BPRC5H50.USD","LU0348767384.USD","LU0540923850.HKD","LU0348827113.USD","06160","BK1583","06821","BK1161","BK1588","BK1500","LU2488822045.USD","LU0634319403.HKD","BK1197","03329","LU1719994722.HKD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620689789","title":"海纳医药三度冲击IPO：现金流吃紧、业绩持续下滑，仿制药CXO的故事不好讲了","url":"https://stock-news.laohu8.com/highlight/detail?id=2620689789","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620689789?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:48","pubTimestamp":1773996480,"startTime":"0","endTime":"0","summary":"国内CXO行业景气度乍暖还寒之际，又一家“卖水人”顶着寒风冲刺港股IPO。南京海纳医药科技股份有限公司近日递表港交所，这已是该公司三年内第三次向资本市场发起冲击。此前，海纳医药经历过创业板IPO折戟，也曾试图“卖身”成都先导实现曲线上市未果，如今在现金流日益紧绷、业绩持续下滑的背景下，火速转道港股。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-20/doc-inhrrrew0753832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","BK1161","CXO","BK1574","159399","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620041459","title":"国信证券：CXO与器械板块机会显现 关注创新药产业链及低估值板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2620041459","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620041459?lang=zh_cn&edition=full","pubTime":"2026-03-17 09:45","pubTimestamp":1773711919,"startTime":"0","endTime":"0","summary":"近期，国产创新药在学术会议上读出优秀的临床数据，建议关注二季度的ASCO等重磅学术会议。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260317/20260317093554_26324.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260317/20260317093554_26324.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0188","BK1574","159992","BK0276","BK1161","BK0183","CXO","002736","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618601607","title":"万联证券：投融资与出海双轮驱动 CXO迎来景气度修复与全球化新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601607","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618601607?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:50","pubTimestamp":1773111055,"startTime":"0","endTime":"0","summary":"医疗健康领域投融资金额持续增加2025年，全球共完成医疗健康领域一级市场投融资1930 笔，累计融资632亿美元，融资金额同比回升8.6%；中国医疗健康产业一级市场共达成797笔投融资交易，累计融资97亿美元，融资金额同比回升32.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","CXO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}